Ethinylestradiol

Generic Name
Ethinylestradiol
Brand Names
Afirmelle 28 Day, Alesse, Altavera 28 Day, Alyacen 1/35, Alyacen 7/7/7, Amethia 91 Day, Amethyst, Annovera, Apri 28 Day, Aranelle 28, Ashlyna 91 Day, Aubra 28 Day, Aurovela, Aurovela Fe, Aviane 28, Ayuna 28 Day Pack, Azurette 28 Day, Balcoltra 28 Day, Balziva 28 Day, Bekyree 28 Day, Beyaz 28 Day, Blisovi 21 Fe 1.5/30 28 Day Pack, Blisovi 21 Fe 1/20 28 Day Pack, Blisovi 24 Fe 1/20 28 Day, Brevicon, Briellyn 28 Day, Camrese 91 Day, Camreselo 91 Day, Caziant 28 Day, Cesia 28 Day, Charlotte 24 Fe Chewable 28 Day, Chateal 28 Day, Cléo -35, Cryselle 28, Cyclafem 1/35 28 Day, Cyclafem 7/7/7 28 Day, Cyestra-35, Cyonanz 28 Day, Cyred 28 Day, Dasetta 1/35 28 Day, Dasetta 7/7/7 28 Day, Daysee 91 Day, Delyla 28 Day, Diane, Dolishale 28 Day, Elinest 28 Day, Eluryng, Emoquette, Enilloring, Enpresse 28 Day, Enskyce 28 Day, Estarylla 28 Day, Evra, Falmina 28 Day, Fayosim 91 Day, Femcon Fe 28 Day, Femhrt 0.5/2.5 28 Day, Femynor 28 Day, Finzala 24 Fe Chewable 28 Day, Freya, Fyavolv, Gemmily 28 Day, Gianvi 28-day, Hailey 1.5/30 21 Day, Hailey 24 Fe 28 Day, Hailey Fe 1.5/30 28 Day, Hailey Fe 1/20 28 Day, Iclevia 91 Day, Indayo, Introvale 91 Day, Isibloom 28 Day, Jaimiess 91 Day, Jasmiel 28 Day, Jinteli, Jolessa 91 Day, Joyeaux 28 Day, Juleber 28 Day, Junel 1.5/30 21 Day, Junel 1/20 21 Day, Junel Fe 1.5/30 28 Day, Junel Fe 1/20 28 Day, Junel Fe 24 1/20 28 Day, Kaitlib Fe 28 Day, Kalliga, Kariva 28 Day, Kelnor 1/35 28 Day, Kelnor 1/50 28 Day, Kurvelo, Larin 1.5/30, Larin 1/20, Larin 24 Fe 1/20, Larin Fe 1.5/30, Larin Fe 1/20, Larissia 28 Day Pack, Layolis Fe 28, Leena 28 Day, Levonest 28 Day, Levora 0.15/30 28 Day, Lillow 28 Day, Linessa, Lo Loestrin Fe 28 Day, Lo Simpesse, Lo-zumandimine 28 Day, Lo/ovral 28 Day, LoJaimiess, Loestrin 1.5/30 21 Day, Loestrin 24 Fe 28 Day, Loestrin Fe 1/20 28 Day, Lolo, Lomedia 24 Fe, Loryna, Loseasonique, Low-ogestrel 28 Day, Lutera 28 Day, Marlissa 28 Day, Marvelon, Melodetta 24 Fe Chewable 28 Day, Merzee 28 Day, Mibelas 24 Fe Chewable 28 Day, Microgestin 1.5/30 21 Day, Microgestin 1/20 21 Day, Microgestin 24 Fe 28 Day, Microgestin Fe 1.5/30 28 Day, Microgestin Fe 1/20 28 Day, Mili 28 Day, Min-ovral, Minastrin 24 Fe Chewable 28 Day, Mircette 28 Day, Mono-linyah 28 Day, Mononessa 28 Day, Myzilra 28 Day, Necon 0.5/35 28 Day, Necon 1/35 28 Day, Necon 7/7/7 28 Day, Nexesta Fe 28 Day, Nikki 28 Day, Nortrel 1/35 21 Day, Nortrel 1/35 28 Day, Nortrel 7/7/7 28 Day, Nuvaring, Nylia 1/35 28 Day, Nylia 7/7/7 28 Day, Nymyo 28 Day, Ocella 28 Day, Orsythia 28 Day, Ortho Tri-cyclen 28 Day, Ortho Tri-cyclen Lo 28 Day, Ortho-novum 7/7/7 28 Day, Philith 28 Day, Pimtrea Pack, Pirmella 1/35 28 Day, Pirmella 7/7/7 28 Day, Portia 28 Day, Previfem 28 Day, Quartette 91 Day Pack, Reclipsen, Rhuzdah 28 Day, Rivelsa 91 Day, Safyral 28 Day, Seasonale, Seasonique, Select, Setlakin 91 Day, Simliya, Simpesse, Sprintec 28 Day, Sronyx 28 Day, Syeda 28 Day, Synphasic, Tarina 24 Fe 1/20 28 Day, Tarina Fe 1/20 28 Day, Taysofy 28 Day, Taytulla 28 Day, Tilia Fe, Tri Femynor 28 Day, Tri-LO- Estarylla 28 Day, Tri-LO-marzia 28-day, Tri-LO-mili, Tri-Lo-Sprintec, Tri-estarylla 28 Day, Tri-legest 28 Day, Tri-linyah, Tri-mili 28 Day, Tri-nymyo 28 Day Pack, Tri-previfem 28 Day, Tri-sprintec 28 Day, Tri-vylibra 28 Day, Tri-vylibra Lo 28 Day, Trinessa 28 Day, Trinessa Lo 28 Day, Triquilar, Trivora 28 Day, Turqoz 28 Day, Twirla 3 Count Weekly Patch, Tyblume 28 Day, Tydemy 28 Day, Velivet 28 Day, Vestura, Vienva 28 Day, Viorele 28 Day, Volnea 28 Day, Vyfemla 28 Day, Vylibra 28 Day, Wera 28 Day, Wymzya Fe 28 Day, Xulane, Yasmin, Yasmin 28 Day, Yaz 28 Day, Yaz Plus, Zafemy, Zarah, Zenchent, Zovia 1/35e 28 Day, Zovia 1/50e 28 Day, Zumandimine 28 Day
Drug Type
Small Molecule
Chemical Formula
C20H24O2
CAS Number
57-63-6
Unique Ingredient Identifier
423D2T571U
Background

Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was developed in an effort to create an estrogen with greater oral bioavailability. These properties were achieved by the substitution of an ethinyl group at carbon 17 of estradiol. Ethinylestradiol soon replaced mestranol in contraceptive pills.
...

Indication

Ethinylestradiol is combined with other drugs for use as a contraceptive, premenstrual dysphoric disorder, moderate acne, moderate to severe vasomotor symptoms of menopause, prevention of postmenopausal osteoporosis.

Associated Conditions
Menopausal Osteoporosis, Mild to Moderate Acne, Premenstrual Dysphoric Disorder (PMDD), Moderate Acne vulgaris, Moderate, severe, Vasomotor Symptoms caused by Menopause
Associated Therapies
Contraception, Folate supplementation therapy

Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome

First Posted Date
2012-05-22
Last Posted Date
2012-05-22
Lead Sponsor
Catholic University of the Sacred Heart
Target Recruit Count
10
Registration Number
NCT01603745
Locations
🇮🇹

Catholic university of Sacred Heart, Rome, Italy

Drug-drug Interaction of BI 201335 and Microgynon

First Posted Date
2012-04-04
Last Posted Date
2015-08-03
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT01570244
Locations
🇩🇪

1220.56.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

New Treatments for Troublesome Bleeding in Implanon Users

Phase 4
Conditions
Interventions
First Posted Date
2011-06-29
Last Posted Date
2011-06-29
Lead Sponsor
Family Planning Association New South Wales
Target Recruit Count
200
Registration Number
NCT01384331
Locations
🇦🇺

Sydney centre for Reproductive Health Research, FPNSW, Sydney, New South Wales, Australia

Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon

First Posted Date
2011-04-04
Last Posted Date
2014-06-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT01328184
Locations
🇩🇪

1245.41.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment

Not Applicable
Terminated
Conditions
Interventions
First Posted Date
2011-02-17
Last Posted Date
2012-10-05
Lead Sponsor
University of Toronto
Target Recruit Count
70
Registration Number
NCT01298128

Evaluation of an Oral Contraceptive Containing 30 mg Ethinyloestradiol and 150 mg Desogestrel on Women's Health

Phase 2
Conditions
Interventions
First Posted Date
2010-12-08
Last Posted Date
2010-12-08
Lead Sponsor
Tehran University of Medical Sciences
Target Recruit Count
61
Registration Number
NCT01256619
Locations
🇮🇷

Tehran University of Medical Sciences-BASIR center, Tehran, Iran, Islamic Republic of

A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

First Posted Date
2010-09-06
Last Posted Date
2019-02-20
Lead Sponsor
ViiV Healthcare
Target Recruit Count
13
Registration Number
NCT01195974
Locations
🇺🇸

GSK Investigational Site, Fargo, North Dakota, United States

Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-10-24
Last Posted Date
2022-02-04
Lead Sponsor
Organon and Co
Target Recruit Count
442
Registration Number
NCT00778999

Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2007-11-29
Last Posted Date
2010-04-22
Lead Sponsor
University of Saskatchewan
Target Recruit Count
41
Registration Number
NCT00565240
Locations
🇨🇦

Royal University Hospital, Saskatoon, Saskatchewan, Canada

A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers

First Posted Date
2007-07-20
Last Posted Date
2012-06-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
22
Registration Number
NCT00504816
Locations
🇺🇸

GSK Investigational Site, Miramar, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath